Stéphane Auvin1, John Irwin2, Paul Abi-Aad3, Alysia Battersby3. 1. Service de Neurologie Pédiatrique, Université Paris Diderot, Paris, France. Electronic address: stephane.auvin@aphp.fr. 2. Zogenix International Ltd., Maidenhead, Berkshire, UK. 3. Wickenstones, Oxfordshire, UK.
Abstract
BACKGROUND: From a disease's first description to its wider recognition, factors such as changes over time in diagnostic criteria, available therapies, and subsequent mortality rates may influence diagnosed prevalence of rare diseases. OBJECTIVES: To propose a novel methodology for estimating the true prevalence of rare diseases using current incidence adjusted to changing diagnostic practice over time. This article focuses on rare diseases whose diagnosis may have changed over time, and raises the hypothesis that prevalence calculated from current incidence may be higher than diagnosed prevalence, which may lag behind the current disease definition and diagnostic methods. A rare epileptic encephalopathy, Dravet syndrome (DS), is explored as an illustrative example. METHODS: A targeted literature review was performed for DS to identify all reported incidence, prevalence, and mortality and depict how diagnostic practice has evolved over time. A conceptual model was developed to calculate prevalence derived from current incidence figures alone (incidence-derived prevalence) or incidence adjusted with factors that cause a diagnostic drag (diagnostic awareness-adjusted prevalence). RESULTS: We identified sufficient publications of incidence and prevalence to test the conceptual model. For pediatric patients with DS, diagnosed prevalence in the field (as reported in current literature) matches incidence-derived prevalence, whereas for adult patients, it is overestimated by incidence-derived prevalence, but not by diagnostic awareness-adjusted prevalence. CONCLUSIONS: Care should be taken with current incidence-derived prevalence figures to not overstate the prevalence in rare diseases, as methodological challenges in counting small populations, coupled with advances in rare disease discovery, may cause discrepancies.
BACKGROUND: From a disease's first description to its wider recognition, factors such as changes over time in diagnostic criteria, available therapies, and subsequent mortality rates may influence diagnosed prevalence of rare diseases. OBJECTIVES: To propose a novel methodology for estimating the true prevalence of rare diseases using current incidence adjusted to changing diagnostic practice over time. This article focuses on rare diseases whose diagnosis may have changed over time, and raises the hypothesis that prevalence calculated from current incidence may be higher than diagnosed prevalence, which may lag behind the current disease definition and diagnostic methods. A rare epilepticencephalopathy, Dravet syndrome (DS), is explored as an illustrative example. METHODS: A targeted literature review was performed for DS to identify all reported incidence, prevalence, and mortality and depict how diagnostic practice has evolved over time. A conceptual model was developed to calculate prevalence derived from current incidence figures alone (incidence-derived prevalence) or incidence adjusted with factors that cause a diagnostic drag (diagnostic awareness-adjusted prevalence). RESULTS: We identified sufficient publications of incidence and prevalence to test the conceptual model. For pediatric patients with DS, diagnosed prevalence in the field (as reported in current literature) matches incidence-derived prevalence, whereas for adult patients, it is overestimated by incidence-derived prevalence, but not by diagnostic awareness-adjusted prevalence. CONCLUSIONS: Care should be taken with current incidence-derived prevalence figures to not overstate the prevalence in rare diseases, as methodological challenges in counting small populations, coupled with advances in rare disease discovery, may cause discrepancies.
Authors: Esmee H Runhart; Patty Dhooge; Magda Meester-Smoor; Jeroen Pas; Jan Willem R Pott; Redmer van Leeuwen; Hester Y Kroes; Arthur A Bergen; Yvonne de Jong-Hesse; Alberta A Thiadens; Mary J van Schooneveld; Maria van Genderen; Camiel Boon; Caroline Klaver; L Ingeborg van den Born; Frans P M Cremers; Carel B Hoyng Journal: Acta Ophthalmol Date: 2021-08-25 Impact factor: 3.988
Authors: Donald B Bailey; Lisa M Gehtland; Megan A Lewis; Holly Peay; Melissa Raspa; Scott M Shone; Jennifer L Taylor; Anne C Wheeler; Michael Cotten; Nancy M P King; Cynthia M Powell; Barbara Biesecker; Christine E Bishop; Beth Lincoln Boyea; Martin Duparc; Blake A Harper; Alex R Kemper; Stacey N Lee; Rebecca Moultrie; Katherine C Okoniewski; Ryan S Paquin; Denise Pettit; Katherine Ackerman Porter; Scott J Zimmerman Journal: BMC Pediatr Date: 2019-07-17 Impact factor: 2.125
Authors: Javier A López-Rivera; Eduardo Pérez-Palma; Joseph Symonds; Amanda S Lindy; Dianalee A McKnight; Costin Leu; Sameer Zuberi; Andreas Brunklaus; Rikke S Møller; Dennis Lal Journal: Brain Date: 2020-04-01 Impact factor: 13.501